IDOLAZZI, Luca
 Distribuzione geografica
Continente #
EU - Europa 8.255
NA - Nord America 7.889
AS - Asia 5.053
SA - Sud America 747
AF - Africa 94
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 9
Totale 22.061
Nazione #
US - Stati Uniti d'America 7.759
RU - Federazione Russa 3.041
GB - Regno Unito 2.123
SG - Singapore 2.008
CN - Cina 1.835
DE - Germania 627
BR - Brasile 610
IT - Italia 587
SE - Svezia 482
FR - Francia 413
HK - Hong Kong 405
IE - Irlanda 390
VN - Vietnam 302
FI - Finlandia 266
KR - Corea 90
TR - Turchia 87
JP - Giappone 84
UA - Ucraina 83
IN - India 82
CA - Canada 67
AR - Argentina 53
NL - Olanda 51
PL - Polonia 41
MX - Messico 40
BD - Bangladesh 34
BE - Belgio 29
ID - Indonesia 28
ES - Italia 27
ZA - Sudafrica 27
AT - Austria 26
EC - Ecuador 23
RO - Romania 17
EG - Egitto 15
CO - Colombia 14
IR - Iran 14
BJ - Benin 11
VE - Venezuela 11
AU - Australia 10
CL - Cile 10
IQ - Iraq 10
PE - Perù 10
UZ - Uzbekistan 10
PY - Paraguay 9
KE - Kenya 8
MA - Marocco 7
PK - Pakistan 7
SA - Arabia Saudita 7
CH - Svizzera 6
NP - Nepal 6
QA - Qatar 6
AL - Albania 5
GR - Grecia 5
LT - Lituania 5
SN - Senegal 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
DZ - Algeria 4
EU - Europa 4
IL - Israele 4
JM - Giamaica 4
KG - Kirghizistan 4
TG - Togo 4
AM - Armenia 3
BG - Bulgaria 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
HR - Croazia 3
LB - Libano 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PA - Panama 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
UY - Uruguay 3
AF - Afghanistan, Repubblica islamica di 2
BO - Bolivia 2
BW - Botswana 2
CU - Cuba 2
DK - Danimarca 2
ET - Etiopia 2
IS - Islanda 2
JO - Giordania 2
LV - Lettonia 2
PT - Portogallo 2
TH - Thailandia 2
TN - Tunisia 2
A1 - Anonimo 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
CM - Camerun 1
CY - Cipro 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GY - Guiana 1
Totale 22.041
Città #
Southend 1.927
Dallas 1.795
Moscow 1.031
Singapore 1.009
Chandler 942
Ashburn 609
Jacksonville 471
Hong Kong 400
Woodbridge 390
Dublin 389
Ann Arbor 315
Beijing 305
Houston 214
The Dalles 168
Lawrence 160
Princeton 160
Wilmington 155
Los Angeles 151
Jinan 145
New York 145
Bologna 128
Redmond 128
Shenyang 127
Nanjing 122
Verona 103
Helsinki 95
Ho Chi Minh City 91
Munich 82
Tokyo 78
Buffalo 74
Hebei 73
Tianjin 73
Hanoi 71
Redondo Beach 57
São Paulo 56
Zhengzhou 55
Changsha 52
Haikou 51
Ningbo 51
Columbus 45
Milan 45
Sindelfingen 43
Taizhou 43
Guangzhou 40
Hangzhou 40
Taiyuan 39
Nanchang 38
Santa Clara 36
Redwood City 34
Warsaw 34
Jiaxing 31
Denver 30
London 29
Chicago 28
San Francisco 28
Brooklyn 27
Seattle 26
Turku 26
Brussels 25
Norwalk 25
Lanzhou 24
Montreal 24
Orem 24
Rome 24
Fuzhou 23
Boardman 22
Hyderabad 22
Washington 22
Atlanta 21
Düsseldorf 21
Toronto 21
Johannesburg 20
Dearborn 19
Amsterdam 18
Brasília 18
Rio de Janeiro 18
Sanayi 18
Lancaster 17
Poplar 17
Manchester 16
Mexico City 16
Phoenix 16
Vienna 16
Chennai 15
Falls Church 15
Nürnberg 15
Orani 15
Porto Alegre 15
Belo Horizonte 14
Falkenstein 14
Jakarta 14
Stockholm 14
Da Nang 13
Fairfield 13
Haiphong 13
Detroit 12
San Jose 12
Campinas 11
Charlotte 11
Cotonou 11
Totale 13.844
Nome #
Italian Multicenter Real-World Study on the Twelve-Month Effectiveness, Safety, and Retention Rate of Guselkumab in Psoriatic Arthritis Patients 329
First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING-SIR registry 320
Teriparatide and denosumab combination therapy and skeletal metabolism 313
A new instrument for the screening of psoriatic arthritis among psoriatic patients 294
Real-World Effectiveness of Bimekizumab in Predominantly Difficult-to-Treat Patients with Psoriatic Arthritis Followed in a Combined Dermatology-Rheumatology Clinic: A 24-Week Multicenter Study 285
CD14(++) CD16(-) monocytes are the main source of 11β-HSD type 1 after IL-4 stimulation 226
Long-term effects of amino-bisphosphonates on circulating gamma-delta T cells 222
Bone Metabolism in a Large Cohort of Patients with Systemic Sclerosis 202
Bone metabolism in patients with anorexia nervosa and amenorrhoea 198
Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed 'window of opportunity' 195
Bone mineral density and bone turnover in premenopausal women with rheumatoid arthritis 194
Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women 194
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis 193
Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. 190
Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab 188
AB0776 18F-Fluoride PET/CT for Detection of Axial Involvement in Ankylosing Spondylitis: 187
Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells 184
A case of mandible Paget’s disease of the bone treated with intravenous neridronate 182
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis 181
Bisphosphonates vs infliximab in ankylosing spondylitis treatment. 180
Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes 180
Bone involvement and osteoporosis in mastocytosis. 176
Concentric left ventricular remodelling is associated with subclinical systolic dysfunction in patients with psoriatic arthritis 176
Comment on: clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial 173
Could γ\δ T-cells explain zoledronic acid adverse events? 169
Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone 169
Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study 169
New strategies for the prevention and treatment of systemic and local bone loss; from pathophysiology to clinical application 168
Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study 167
Bone involvement in patient with clonal mast cell disorders 166
18F-fluoride PET/CT for detection of axial involvement in ankylosing spondylitis: correlation with disease activity 166
Teriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I. 165
Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis 165
Serum Levels of Tryptase Suggest That Mast Cells Might Have an Antiinflammatory Role in Rheumatoid Arthritis: Comment on the Article by Rivellese et al 161
Prevalence and incidence of rheumatoid arthritis in Italy. 160
Prednisone compared to methysprednisolone in the polymyalgia rheumatica treatment 159
Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis 159
Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE) 158
Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series 157
Correction to: Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis? 157
Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis 152
Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare 152
In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls 151
DXA bone mineral density in males: retrospective study in real life. 150
Dose-dependent short-term effects of single high doses of oral vitamin D3 on bone turnover markers 148
Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis. 148
Effects of denosumab on peripheral lymphocyte subpopulations 148
Suboptimal methotrexate use in rheumatoid arthritis patients in Italy: the MARI study 145
Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial 144
Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis 144
Prevalence of osteoporosis in patients affected by mastocytosis 143
Sclerostin and DKK1 in postmenopausal osteoporosis treated with Denosumab. 141
Development and First Validation of a Disease Activity Score for Gout 140
Disease Activity and Anticitrullinated Peptide Antibody Positivity Predict the Worsening of Ventricular Function in Rheumatoid Arthritis 140
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases 140
Sclerostin and DKK1 in primary hyperparathyroidism. 137
Diffuse idiopathic skeletal hyperostosis (DISH) in type 2 diabetes: a new imaging possibility and a new biomarker 137
Osteoporosis: an Independent Determinant of Bone Erosions in Rheumatoid Arthritis? 136
Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis? 136
Osteopetrosi 135
In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density 135
Vitamin D levels in patients with psoriasis with or without arthritis 134
Denosumab, cortical bone and bone erosions in rheumatoid arthritis 134
Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis 134
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis 132
Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis 132
Focal bone involvement in inflammatory arthritis: the role of IL17 131
Improvements in the management of rheumatic patients from vertebral imagee obtained through dual-energy X-ray absorptiometry. 130
Relationship Between Increased Fecal Calprotectin Levels and Interstitial Lung Disease in Systemic Sclerosis 130
Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study 129
Hypophosphatasia in adults: A new manifestation, a new mutation. A case report 129
Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis 128
Periostin: The bone and beyond 128
Drug-induced osteonecrosis of the jaw: the state of the art 127
The ultrasonographic study of the nail reveals differences in patients affected by inflammatory and degenerative conditions 127
Correction to: The ultrasonographic study of the nail reveals differences in patients affected by inflammatory and degenerative conditions 127
Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID) 127
Duration of treatment for osteoporosis 127
Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome 127
Surgical Treatment of Symptomatic Aortic Aneurysm in a Patient with Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: Case Report and Review of the Literature 125
Vitamin D levels strongly influence bone mineral density and bone turnover markers during weight gain in female patients with anorexia nervosa 124
Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators 124
Rheumatoid arthritis, γδ T cells and bisphosphonates 123
The obesity paradox and osteoporosis 123
MEDAL con etoricoxib: l’inizio di una nuova era per il trattamento del dolore muscolo scheletrico 122
Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides? 122
Short-term effects on bone turnover markers of a single high dose of oral vitamin D₃. 120
Osteoporosi ed attività sportiva: 119
Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. 119
Could nail and joint alterations make the difference between psoriatic arthritis and osteoarthritis during the ultrasonographic evaluation of the distal interphalangeal joints? 119
Enthesitis of the hands in psoriatic arthritis: an ultrasonographic perspective 119
Ruolo della vitamina D 118
Long-term consequences of a treatment course with bisphosphonates in primary hyperparathyroidism 118
Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica is Uncommon but May Be Enhanced by Amino Bisphosphonates 118
Operator-independent quantitative chest computed tomography versus standard assessment of interstitial lung disease related to systemic sclerosis: A multi-centric study 117
Strong relationship between vitamin D status and bone mineral density in anorexia nervosa 117
The ultrasonographic spectrum of toe dactylitis in psoriatic arthritis: a descriptive analysis 116
Previous use of amino-bisphosphonates and circulating gamma/delta T cells 116
Zoledronic Acid in Osteoporosis Secondary to Mastocytosis. 116
Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients 116
Totale 15.623
Categoria #
all - tutte 73.579
article - articoli 72.597
book - libri 0
conference - conferenze 594
curatela - curatele 0
other - altro 388
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 147.158


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021427 0 0 0 0 0 122 20 43 81 11 107 43
2021/20221.206 93 347 7 62 54 29 24 65 81 24 85 335
2022/20232.688 191 289 242 491 213 650 45 145 291 30 76 25
2023/20241.251 54 113 107 152 158 180 60 126 6 37 189 69
2024/20253.160 152 221 152 493 145 111 163 147 472 262 282 560
2025/20268.019 720 506 1.906 1.674 2.568 645 0 0 0 0 0 0
Totale 22.401